Physician profile
Bill G Sbiliris
NPI 1710017355
$6,805.74
in general payments reported to CMS, 2019-2025
9 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,580 · 2020: $85.98 · 2021: $430 · 2022: $373 · 2023: $251 · 2024: $604 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $5,384.91 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Janssen Scientific Affairs, LLC | $366.62 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $300.26 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $222.02 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Indivior INC. | $166.17 | 2019-2024 | Perseris |
| Allergan, INC. | $147.38 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $124.90 | 2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $46.57 | 2025 | Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Sbiliris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.